Form 4: Biogen Executive Priya Singhal Reports Stock Transactions

Priya Singhal, Head of Development at Biogen, reported the acquisition of 1,828 shares of common stock through the vesting of restricted stock units and the disposal of 578 shares to cover tax obligations.

Summary

• Priya Singhal, Head of Development at Biogen, filed a Form 4 disclosing changes in her beneficial ownership of Biogen stock.
• On January 31, 2025, Ms. Singhal acquired 1,828 shares of common stock through the vesting of restricted stock units.
• Also on January 31, 2025, she disposed of 578 shares of common stock at a price of $143.93 per share to cover tax obligations.
• Following these transactions, Ms. Singhal beneficially owns 6,676.4761 shares of Biogen common stock directly.
• The restricted stock units were granted on February 1, 2023, and vest in three equal installments on each anniversary of the grant date.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of stock transactions by an executive, which is neither positive nor negative in itself. It is a standard regulatory filing.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is common in publicly traded companies. It provides transparency into the ownership changes of company stock by insiders.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency of insider transactions.
• The vesting schedule of the restricted stock units, with three equal annual installments, is a common practice for executive compensation.
• The sale of shares to cover tax obligations is a typical occurrence when restricted stock units vest.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect routine executive compensation and tax obligations.

Key Dates

Keywords

Biogen, Priya Singhal, stock transaction, Form 4, restricted stock units, insider trading, executive compensation